logo-loader
viewDyadic International Inc

Full interview: Dyadic International reveals newest research collaboration

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the biotech saw continued momentum with a research collaboration deal signed with a 'top tier' pharma company. 

Emalfarb, who also discussed the firm's second quarter earnings, says this pharma company is aligned with Dyadic's work, and it has its own division focused on using microbial organisms to replace Chinese hamster ovary cells. 

Quick facts: Dyadic International Inc

Price: 4.82 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $131.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Dyadic CEO remarks on steps the federal gov't can take to speed along drug...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb sat down with Proactive at the Biotech Showcase 2020 in San Francisco. Emalfarb talks about how there's a lot of things the government can do to speed the development of new biologics to the market. Namely, by offering a simliar orphan...

on 01/16/2020

2 min read